Acquired by Inotiv ILS is now part of Inotiv's nonclinical and analytical drug discovery platform, which expands potential cross-sell opportunities into a larger customer base and integrated service offerings.

Regulatory compliant Specializes in in vivo and in vitro toxicology, genetic toxicology, computational toxicology, histology, and pathology with compliance to national and international regulations, enabling collaboration with regulated industries such as federal government, biopharma, chemical, and consumer products.

Diverse client mix Serves federal agencies and multiple industries (biopharma, chemical, agrochemical, food additive, consumer products), presenting multiple entry points for expanding contracts and bundled testing services.

Compact scale Mid-sized CRO with experienced leadership and a scope that supports flexible service models, offering personalized engagement to win new projects from larger competitors through niche toxicology and molecular biology capabilities.

Revenue growth potential Reported revenue range of 10–25 million suggests room to scale with expanded offerings, higher-value toxicology studies, and deeper regulatory submissions, aligned with Inotiv’s platform to accelerate growth.